{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:02:30Z","timestamp":1791295350724,"version":"4.1.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.2217\/nmt.15.52","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T09:44:45Z","timestamp":1449222285000},"page":"497-504","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["IFN-\u03b3 for Friedreich Ataxia: Present Evidence"],"prefix":"10.1080","volume":"5","author":[{"given":"McKenzie","family":"Wells","sequence":"first","affiliation":[{"name":"Departments of Pediatrics &amp; Neurology Children\u2019s Hospital of Philadelphia\rPhiladelphia\rPA\rUSA"},{"name":"Perelman School of Medicine University of Pennsylvania\rPhiladelphia\rPA\r19104\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Seyer","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics &amp; Neurology Children\u2019s Hospital of Philadelphia\rPhiladelphia\rPA\rUSA"},{"name":"Perelman School of Medicine University of Pennsylvania\rPhiladelphia\rPA\r19104\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Schadt","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics &amp; Neurology Children\u2019s Hospital of Philadelphia\rPhiladelphia\rPA\rUSA"},{"name":"Perelman School of Medicine University of Pennsylvania\rPhiladelphia\rPA\r19104\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Lynch","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics &amp; Neurology Children\u2019s Hospital of Philadelphia\rPhiladelphia\rPA\rUSA"},{"name":"Perelman School of Medicine University of Pennsylvania\rPhiladelphia\rPA\r19104\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,12,4]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5254.1423"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.5.743"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073812449691"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000218155.46739.90"},{"issue":"5","key":"e_1_3_2_7_1","first-page":"1251","article-title":"Atypical Friedreich ataxia caused by compound heterozygosity for a novel Missense mutation and the GAA triplet-repeat expansion","volume":"60","author":"Bidichandani SI","year":"1997","unstructured":"Bidichandani SI , AshizawaT, PatelPI . Atypical Friedreich ataxia caused by compound heterozygosity for a novel Missense mutation and the GAA triplet-repeat expansion . Am. J. Hum. Genet.60 ( 5 ), 1251 \u2013 1256 ( 1997 ).","journal-title":"Am. J. Hum. Genet."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12337"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2008.06847.x"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.118679"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1579"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja027967i"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1709"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/303056"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1097-215"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.01.010"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2010.07.001"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.168"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25058"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.10.008"},{"key":"e_1_3_2_21_1","first-page":"4","article-title":"Antioxidants and other pharmacological treatments for Friedreich ataxia","volume":"18","author":"Kearney M","year":"2012","unstructured":"Kearney M , OrrellRW, FaheyM, PandolfoM . Antioxidants and other pharmacological treatments for Friedreich ataxia . Cochrane Database Syst. Rev.18, 4 ( 2012 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24248"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12141"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-010-0212-7"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/2053-8871-1-10"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25836"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24066"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001958"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.02.016"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044498"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2015.1083854"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds110"},{"key":"e_1_3_2_33_1","unstructured":"Clinical Trials Database: NCT02035020 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02035020 ."},{"key":"e_1_3_2_34_1","unstructured":"Clinical Trials Database: NCT02415127 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415127 ."},{"key":"e_1_3_2_35_1","unstructured":"ACTIMMUNE (interferon gamma-1b) full prescribing information . Vidara Therapeutics Research Ltd Roswell GA USA ( 2013 )."},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199502000-00014"},{"key":"e_1_3_2_37_1","unstructured":"Peprotech: Manufacturer of Quality Cytokine Products: Recombinant Human IFN-\u03b3 . Peprotech Rocky Hill NJ USA ( 2015 ). www.peprotech.com\/en-US\/Pages\/Product\/Recombinant_Human_IFN-\u03b3\/300\u2013302 ."},{"key":"e_1_3_2_38_1","first-page":"97","article-title":"IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications","volume":"316","author":"Young HA","year":"2007","unstructured":"Young HA , BreamJH . IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications . Curr Top. Microbiol. Immunol.316, 97 \u2013 117 ( 2007 ).","journal-title":"Curr Top. Microbiol. Immunol."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.01.011"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2010.01529.x"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838505"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116318"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.1998.00323.x"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1107781"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0407216"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.9.6220"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707704200"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440121"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200005)47:5<659::AID-ANA17>3.0.CO;2-T"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02740619"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.02.020"},{"issue":"4","key":"e_1_3_2_52_1","first-page":"654","article-title":"A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels","volume":"23","author":"Polisson RP","year":"1996","unstructured":"Polisson RP , GilkesonGS, PyunEH, PisetskyDS, SmithEA, SimonLS . A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels . J. Rheumatol.23 ( 4 ), 654 \u2013 658 ( 1996 ).","journal-title":"J. Rheumatol."}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt.15.52","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:47:45Z","timestamp":1716493665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt.15.52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.2217\/nmt.15.52"],"URL":"https:\/\/doi.org\/10.2217\/nmt.15.52","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}